Sign In
Buy LUCD
$1.01
-0.0250 (-2.43%)
At Close: Jun 03, 2026
Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025
09:16am, Friday, 05'th Sep 2025
Conference call scheduled for Monday, September 8, at 8:30 AM ET to discuss September 4 MolDX Contractor Advisory Committee (CAC) meeting NEW YORK , Sept. 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc
Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025
08:00am, Wednesday, 27'th Aug 2025
Fireside chat with Chairman & CEO Lishan Aklog, M.D., scheduled for Friday, September 5, at 8:35 AM EDT NEW YORK , Aug. 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or th
PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology
08:01am, Tuesday, 26'th Aug 2025
Newly-formed PAVmed subsidiary to license endoscopic imaging technology designed to identify and facilitate ablative treatment of esophageal dysplasia Lucid Diagnostics to collaborate with PAVmed as a
PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results
08:00am, Thursday, 14'th Aug 2025
Lucid processed 2,756 EsoGuard® 2Q25 tests, recognized revenue of $1.2 million,and secured CAC meeting on Medicare LCD for EsoGuard to be held on September4 Veris Health completed 2Q25 financing, rel
Lucid Diagnostics Inc. (LUCD) Q2 2025 Earnings Call Transcript
04:39pm, Wednesday, 13'th Aug 2025
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q2 2025 Earnings Call August 13, 2025 8:30 AM ET Company Participants Dennis M. McGrath - Chief Financial Officer Lishan Aklog - Chairman & CEO Matthew Riley - Di
Lucid Diagnostics Inc. (LUCD) Reports Q2 Loss, Tops Revenue Estimates
10:15am, Wednesday, 13'th Aug 2025
Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.2 per share a year ago.
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results
08:00am, Wednesday, 13'th Aug 2025
Processed 2,756 EsoGuard® tests and recognized 2Q25 revenue of $1.2 million, ending quarter with over $30 million in proforma cash and extending runway well past upcoming reimbursement milestones Mul
Lucid Diagnostics to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 05'th Aug 2025
NEW YORK , Aug. 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed
PAVmed to Hold a Business Update Conference Call and Webcast on August 14, 2025
08:01am, Thursday, 31'st Jul 2025
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , July 31, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technolo
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025
08:01am, Wednesday, 30'th Jul 2025
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , July 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention m
PAVmed Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
08:00am, Wednesday, 30'th Jul 2025
NEW YORK , July 30, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnosti
MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test
07:31am, Wednesday, 16'th Jul 2025
Virtual public CAC meeting to be held September 4, 2025, at 2:00 p.m. ET NEW YORK , July 16, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage
Lucid to partner with Hoag in its mission to eradicate esophageal cancer by expanding access to EsoGuard precancer testing across its extensive healthcare delivery network NEW YORK , June 18, 2025 /PR
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes
07:31am, Tuesday, 27'th May 2025
NEW YORK , May 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed
PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results
08:01am, Thursday, 15'th May 2025
Lucid secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash Veris Health completed 1Q25 financing, resumed development of
